ADAR1 Capital Management LLC Acquires Shares of 313,354 Arvinas, Inc. $ARVN

Key Points

• ADAR1 Capital Management LLC acquired 313,354 shares of Arvinas, Inc., valued at approximately $2.2 million, representing a 0.43% ownership of the company.
• Arvinas reported a quarterly loss of ($0.84) EPS, but it beat analysts' expectations and the revenue was down 70.7% year-over-year.
• Institutional investors own 95.19% of Arvinas stock, with multiple firms significantly increasing their stakes recently.

ADAR1 Capital Management LLC acquired a new stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 313,354 shares of the company's stock, valued at approximately $2,200,000. ADAR1 Capital Management LLC owned approximately 0.43% of Arvinas as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Arvinas by 3.8% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,514 shares of the company's stock worth $700,000 after buying an additional 1,353 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Arvinas in the fourth quarter worth about $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Arvinas by 0.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 433,531 shares of the company's stock worth $8,311,000 after acquiring an additional 3,047 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Arvinas by 3.8% during the first quarter. Rhumbline Advisers now owns 91,210 shares of the company's stock valued at $640,000 after acquiring an additional 3,333 shares in the last quarter. Finally, Hsbc Holdings PLC raised its position in shares of Arvinas by 22.7% in the 4th quarter. Hsbc Holdings PLC now owns 19,220 shares of the company's stock valued at $365,000 after purchasing an additional 3,551 shares during the last quarter. 95.19% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Arvinas news, CFO Andrew Saik sold 5,700 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $7.61, for a total transaction of $43,377.00. Following the transaction, the chief financial officer directly owned 164,401 shares of the company's stock, valued at $1,251,091.61. This trade represents a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.73% of the company's stock.

Analyst Upgrades and Downgrades

ARVN has been the topic of several research analyst reports. HC Wainwright dropped their target price on shares of Arvinas from $24.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, August 7th. UBS Group dropped their price objective on shares of Arvinas from $74.00 to $21.00 and set a "buy" rating on the stock in a report on Thursday, May 15th. Leerink Partners reissued a "market perform" rating and issued a $9.00 target price (down from $10.00) on shares of Arvinas in a research report on Monday, June 2nd. Wells Fargo & Company dropped their target price on Arvinas from $19.00 to $16.00 and set an "overweight" rating on the stock in a research report on Thursday, August 7th. Finally, Leerink Partnrs downgraded shares of Arvinas from a "strong-buy" rating to a "hold" rating in a report on Sunday, June 1st. Twelve equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, Arvinas has a consensus rating of "Moderate Buy" and a consensus price target of $19.76.

Arvinas Stock Up 2.9%

Shares of ARVN stock traded up $0.22 during mid-day trading on Friday, hitting $7.83. 1,891,283 shares of the stock were exchanged, compared to its average volume of 1,457,613. Arvinas, Inc. has a 52-week low of $5.90 and a 52-week high of $29.61. The firm has a fifty day moving average of $7.50 and a 200 day moving average of $8.41. The company has a market cap of $574.86 million, a PE ratio of -7.75 and a beta of 2.38.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.87) by $0.03. Arvinas had a negative return on equity of 12.01% and a negative net margin of 19.47%.The company had revenue of $22.40 million for the quarter, compared to the consensus estimate of $34.42 million. During the same quarter in the prior year, the business posted ($0.49) earnings per share. Arvinas's revenue for the quarter was down 70.7% on a year-over-year basis. Equities analysts predict that Arvinas, Inc. will post -3.81 EPS for the current year.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.